Title

Randomized Double-Blind Cross-Over Study of Sinemet-Controlled Release (CR4 50/200) Versus Sinemet 25/100 in Parkinson's Disease

Department

neurology

Document Type

Article

Abstract

Sinemet-controlled release (CR4) consisting of 50 mg carbidopa/200 mg levodopa was compared with Sinemet 25/100 in 24 Parkinson’s disease (PD) patients during a 16-week double-blind cross-over study. The mean age of the patients was 66.2 years, their mean duration of PD was 9.3 years. All of the patients had response fluctuations consisting mainly of the ‘wearing-off’ phenomenon. Some of the patients also experienced the ‘on-off’ phenomenon. All patients were evaluated using the unified Parkinson disease rating scale. The following significant differences were noted on Sinemet CR4. More patients noted a decrease in dyskinesias and response fluctuations; more patients experienced a decrease in stage when ‘on’: more patients were ‘on’ longer during the day. and more patients were globally improved. The mean number of doses per day were significantly less on Sinemet CR4 (mean 5.0, range 3-8) than on Sinemet 25/100 (mean 6.2, range 4-11 doses/day). The mean dose of levodopa in Sinemet CR4 was 1,186 ± 458 mg and the mean dose of carbidopa was 797 ± 115 mg. The mean dose of levodopa in Sinemet 25/100 was 873 ± 304 mg and the mean dose of carbidopa was 218 ± 76 mg. This study indicates that Sinemet CR4 is a useful addition for patients with response fluctuations. © 1990 S. Karger AG, Basel.

Medical Subject Headings

neurology

Publication Date

1990

Publication Title

European Neurology

ISSN

143022

Volume

30

Issue

2

First Page

75

Last Page

78

Digital Object Identifier (DOI)

10.1159/000117314

This document is currently not available here.

Share

COinS